Literature DB >> 23073473

Insights into the epigenetic mechanisms controlling pancreatic carcinogenesis.

Angela L McCleary-Wheeler1, Gwen A Lomberk, Frank U Weiss, Günter Schneider, Muller Fabbri, Tara L Poshusta, Nelson J Dusetti, Sandra Baumgart, Juan L Iovanna, Volker Ellenrieder, Raul Urrutia, Martin E Fernandez-Zapico.   

Abstract

During the last couple decades, we have significantly advanced our understanding of mechanisms underlying the development of pancreatic ductual adenocarcinoma (PDAC). In the late 1990s into the early 2000s, a model of PDAC development and progression was developed as a multi-step process associated with the accumulation of somatic mutations. The correlation and association of these particular genetic aberrations with the establishment and progression of PDAC has revolutionized our understanding of this process. However, this model leaves out other molecular events involved in PDAC pathogenesis that contribute to its development and maintenance, specifically those being epigenetic events. Thus, a new model considering the new scientific paradigms of epigenetics will provide a more comprehensive and useful framework for understanding the pathophysiological mechanisms underlying this disease. Epigenetics is defined as the type of inheritance not based on a particular DNA sequence but rather traits that are passed to the next generation via DNA and histone modifications as well as microRNA-dependent mechanisms. Key tumor suppressors that are well established to play a role in PDAC may be altered through hypermethylation, and oncogenes can be upregulated secondary to permissive histone modifications. Factors involved in tumor invasiveness can be aberrantly expressed through dysregulated microRNAs. A noteworthy characteristic of epigenetic-based inheritance is its reversibility, which is in contrast to the stable nature of DNA sequence-based alterations. Given this nature of epigenetic alterations, it becomes imperative that our understanding of epigenetic-based events promoting and maintaining PDAC continues to grow.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23073473      PMCID: PMC3513548          DOI: 10.1016/j.canlet.2012.10.005

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  90 in total

Review 1.  Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome.

Authors:  R D Kornberg; Y Lorch
Journal:  Cell       Date:  1999-08-06       Impact factor: 41.582

2.  Transplantation of nuclei in newt's eggs.

Authors:  C H WADDINGTON; E M PANTELOURIS
Journal:  Nature       Date:  1953-12-05       Impact factor: 49.962

Review 3.  Regulated nucleosome mobility and the histone code.

Authors:  Michael S Cosgrove; Jef D Boeke; Cynthia Wolberger
Journal:  Nat Struct Mol Biol       Date:  2004-11       Impact factor: 15.369

4.  Summary: epigenetics--from phenomenon to field.

Authors:  D E Gottschling
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2004

Review 5.  The (dual) origin of epigenetics.

Authors:  D Haig
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2004

Review 6.  The histone tails of the nucleosome.

Authors:  K Luger; T J Richmond
Journal:  Curr Opin Genet Dev       Date:  1998-04       Impact factor: 5.578

7.  Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis.

Authors:  Martin E Fernandez-Zapico; Natalia C Gonzalez-Paz; Ellen Weiss; Doris N Savoy; Julian R Molina; Rafael Fonseca; Thomas C Smyrk; Suresh T Chari; Raul Urrutia; Daniel D Billadeau
Journal:  Cancer Cell       Date:  2005-01       Impact factor: 31.743

Review 8.  Eukaryotic cytosine methyltransferases.

Authors:  Mary Grace Goll; Timothy H Bestor
Journal:  Annu Rev Biochem       Date:  2005       Impact factor: 23.643

9.  A mammalian protein with specific demethylase activity for mCpG DNA.

Authors:  S K Bhattacharya; S Ramchandani; N Cervoni; M Szyf
Journal:  Nature       Date:  1999-02-18       Impact factor: 49.962

10.  Sialylated MUC1 mucin expression in normal pancreas, benign pancreatic lesions, and pancreatic ductal adenocarcinoma.

Authors:  Y Masaki; M Oka; Y Ogura; T Ueno; K Nishihara; A Tangoku; M Takahashi; M Yamamoto; T Irimura
Journal:  Hepatogastroenterology       Date:  1999 Jul-Aug
View more
  34 in total

Review 1.  The Triple-Code Model for Pancreatic Cancer: Cross Talk Among Genetics, Epigenetics, and Nuclear Structure.

Authors:  Gwen A Lomberk; Raul Urrutia
Journal:  Surg Clin North Am       Date:  2015-07-23       Impact factor: 2.741

2.  Pancreatic cancer-associated retinoblastoma 1 dysfunction enables TGF-β to promote proliferation.

Authors:  A Jesse Gore; Samantha L Deitz; Lakshmi Reddy Palam; Kelly E Craven; Murray Korc
Journal:  J Clin Invest       Date:  2013-12-16       Impact factor: 14.808

3.  Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma.

Authors:  Pawel K Mazur; Alexander Herner; Stephano S Mello; Matthias Wirth; Simone Hausmann; Francisco J Sánchez-Rivera; Shane M Lofgren; Timo Kuschma; Stephan A Hahn; Deepak Vangala; Marija Trajkovic-Arsic; Aayush Gupta; Irina Heid; Peter B Noël; Rickmer Braren; Mert Erkan; Jörg Kleeff; Bence Sipos; Leanne C Sayles; Mathias Heikenwalder; Elisabeth Heßmann; Volker Ellenrieder; Irene Esposito; Tyler Jacks; James E Bradner; Purvesh Khatri; E Alejandro Sweet-Cordero; Laura D Attardi; Roland M Schmid; Guenter Schneider; Julien Sage; Jens T Siveke
Journal:  Nat Med       Date:  2015-09-21       Impact factor: 53.440

4.  Class I histone deacetylase inhibition improves pancreatitis outcome by limiting leukocyte recruitment and acinar-to-ductal metaplasia.

Authors:  Marta Bombardo; Enrica Saponara; Ermanno Malagola; Rong Chen; Gitta M Seleznik; Cecile Haumaitre; Evans Quilichini; Anja Zabel; Theresia Reding; Rolf Graf; Sabrina Sonda
Journal:  Br J Pharmacol       Date:  2017-09-20       Impact factor: 8.739

Review 5.  Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians.

Authors:  Rosella Spadi; Federica Brusa; Agostino Ponzetti; Isabella Chiappino; Nadia Birocco; Libero Ciuffreda; Maria Antonietta Satolli
Journal:  World J Clin Oncol       Date:  2016-02-10

6.  Clinical significance of RECK promoter methylation in pancreatic ductal adenocarcinoma.

Authors:  Xiong-Xiong Lu; Shu-Min Zhang; Yuan Fang; Zheng-Ting Wang; Jun-Jie Xie; Qian Zhan; Xia-Xing Deng; Hao Chen; Jia-Bin Jin; Cheng-Hong Peng; Hong-Wei Li; Bai-Yong Shen
Journal:  Tumour Biol       Date:  2013-06-08

7.  Inhibition of S-Adenosylmethionine-Dependent Methyltransferase Attenuates TGFβ1-Induced EMT and Metastasis in Pancreatic Cancer: Putative Roles of miR-663a and miR-4787-5p.

Authors:  Hardik R Mody; Sau Wai Hung; Mohammad AlSaggar; Jazmine Griffin; Rajgopal Govindarajan
Journal:  Mol Cancer Res       Date:  2016-09-13       Impact factor: 5.852

Review 8.  [Will molecular diagnostics become established in pancreatic pathology?].

Authors:  B Sipos; J Sperveslage
Journal:  Pathologe       Date:  2013-11       Impact factor: 1.011

Review 9.  Mechanistic insights into self-reinforcing processes driving abnormal histogenesis during the development of pancreatic cancer.

Authors:  Juan L Iovanna; David L Marks; Martin E Fernandez-Zapico; Raul Urrutia
Journal:  Am J Pathol       Date:  2013-01-31       Impact factor: 4.307

10.  DLC-1 is a candidate biomarker methylated and down-regulated in pancreatic ductal adenocarcinoma.

Authors:  Yu-Zheng Xue; Tie-Long Wu; Yan-Min Wu; Ying-Yue Sheng; Zhe-Qiang Wei; Yu-Feng Lu; Li-Hua Yu; Jian-Ping Li; Zhao-Shen Li
Journal:  Tumour Biol       Date:  2013-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.